CELLECTAR BIOSCIENCES INC (CLRB)
US15117F8077 - Common Stock
CELLECTAR BIOSCIENCES INC
NASDAQ:CLRB (9/13/2024, 8:06:40 PM)
Premarket: 2.1 -0.03 (-1.41%)2.13
+0.02 (+0.95%)
Company Profile
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 20 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Company Info
CELLECTAR BIOSCIENCES INC
100 Campus Drive
Florham Park NEW JERSEY 07932
P: 16084418120
CEO: JamesV.Caruso
Employees: 20
Website: https://www.cellectar.com/
CLRB News
21 days ago - Cellectar BiosciencesIopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s MacroglobulinemiaJorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D. to Review CLOVER WaM Pivotal Study FLORHAM PARK,...
24 days ago - Cellectar BiosciencesCellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from NasdaqFLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
a month ago - Cellectar BiosciencesCellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate UpdateManagement to host a conference call today at 8:30 am ET...
a month ago - Cellectar BiosciencesUPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
2 months ago - Cellectar BiosciencesCellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months80% Overall Response Rate Achieved...
2 months ago - Cellectar BiosciencesCellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 MillionFLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
CLRB Twits
Here you can normally see the latest stock twits on CLRB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
